These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 26603525)

  • 1. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
    Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
    Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
    Sasaki M; Kato D; Murakami K; Yoshida H; Takase S; Otsubo T; Ogiwara H
    Nat Commun; 2024 Jun; 15(1):4770. PubMed ID: 38839769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
    Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
    Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction.
    Baluchamy S; Sankar N; Navaraj A; Moran E; Thimmapaya B
    Oncogene; 2007 Feb; 26(5):781-7. PubMed ID: 16862175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT.
    Liu Y; Yang EJ; Shi C; Mou PK; Zhang B; Wu C; Lyu J; Shim JS
    Int J Biol Sci; 2020; 16(11):1774-1784. PubMed ID: 32398948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells
    Li J; Huang C; Xiong T; Zhuang C; Zhuang C; Li Y; Ye J; Gui Y
    Int J Biol Sci; 2019; 15(6):1276-1286. PubMed ID: 31223286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
    Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
    Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recruitment of nuclear factor Y to the inverted CCAAT element (ICE) by c-Jun and E1A stimulates basal transcription of the bone sialoprotein gene in osteosarcoma cells.
    Su M; Bansal AK; Mantovani R; Sodek J
    J Biol Chem; 2005 Nov; 280(46):38365-75. PubMed ID: 16087680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
    Korzus E
    Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition.
    Wang F; Marshall CB; Ikura M
    Cell Mol Life Sci; 2013 Nov; 70(21):3989-4008. PubMed ID: 23307074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of p300 and CBP disrupts histone acetylation at the mouse Sry promoter and causes XY gonadal sex reversal.
    Carré GA; Siggers P; Xipolita M; Brindle P; Lutz B; Wells S; Greenfield A
    Hum Mol Genet; 2018 Jan; 27(1):190-198. PubMed ID: 29145650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription.
    Faiola F; Liu X; Lo S; Pan S; Zhang K; Lymar E; Farina A; Martinez E
    Mol Cell Biol; 2005 Dec; 25(23):10220-34. PubMed ID: 16287840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting AURKA to induce synthetic lethality in CREBBP-deficient B-cell malignancies via attenuation of MYC expression.
    Sun Y; Chen J; Hong JH; Xiao R; Teng Y; Wang P; Deng P; Yu Z; Chan JY; Chai KXY; Gao J; Wang Y; Pan L; Liu L; Liu S; Teh BT; Yu Q; Lim ST; Li W; Xu B; Ong CK; Tan J
    Oncogene; 2024 Jul; 43(28):2172-2183. PubMed ID: 38783101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.
    Attar N; Kurdistani SK
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27881443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice.
    Ichise T; Yoshida N; Ichise H
    J Pathol; 2019 Sep; 249(1):39-51. PubMed ID: 30953353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CBP/p300 acetyltransferase activity in hematologic malignancies.
    Dutta R; Tiu B; Sakamoto KM
    Mol Genet Metab; 2016 Sep; 119(1-2):37-43. PubMed ID: 27380996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
    Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
    Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
    Haery L; Mussakhan S; Waxman DJ; Gilmore TD
    Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.